Drug overlaps, shortages may complicate Teva bid for Mylan

Published 11y ago

NEW YORK (Reuters) – Teva Pharmaceutical Industries’ bid for Mylan NV would create a company controlling nearly 25 percent of the U.S. generics market, including drugs in short supply, according to industry experts and a Reuters review of regulatory filings. B... More »